Lanean...
Nanoformulations of Anticancer FGFR Inhibitors with Improved Therapeutic Index
Fibroblast growth factor receptor (FGFR) inhibitors like ponatinib and nintedanib are clinically approved for defined cancer patient cohorts but often exert dose-limiting adverse effects. Hence, we encapsulated FGFR inhibitors ponatinib, PD173074, and nintedanib into polylactic acid nanoparticles an...
Gorde:
| Argitaratua izan da: | Nanomedicine |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7611408/ https://ncbi.nlm.nih.gov/pubmed/30121385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nano.2018.08.001 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|